Yanucil, Christopher
Kentrup, Dominik
Li, Xueyi
Grabner, Alexander
Schramm, Karla
Martinez, Eliana C.
Li, Jinliang
Campos, Isaac
Czaya, Brian
Heitman, Kylie
Westbrook, David
Wende, Adam R.
Sloan, Alexis
Roche, Johanna M.
Fornoni, Alessia
Kapiloff, Michael S.
Faul, Christian
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (F31DK115074, F31DK117550, R01DK117599)
National Heart, Lung, and Blood Institute (R01HL133011, R01HL146111, R01HL128714)
National Cancer Institute (R01CA227493)
Article History
Received: 29 September 2021
Accepted: 18 April 2022
First Online: 5 May 2022
Competing interests
: C.F. and D.K. have served as consultants for Bayer, and C.F. also for Calico Labs. C.Y. and C.F. are inventors on two pending patents (PCT/US2019/049211; PCT/US19/49161) and they are co-founders of a startup biotech company (Alpha Young LLC). C.F. is also the CSO of Alpha Young LLC. C.F. has a patent on FGFR inhibition (European Patent No. 2723391). C.F. and A.G. received honoraria for publishing a book (“FGF23”, Elsevier, ISBN9780128180365). A.F. is vice-president of L&F Health LLC and the scientist co-founder and a shareholder of ZyVersa Therapeutics Inc and River 3 Renal Corp. X.L., K.S., E.C.M., J.L., I.C., B.C., K.H., D.W., A.R.W., A.S., J.M.R. and M.S.K. have no competing interest.